Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.570
+0.020 (0.78%)
At close: Nov 6, 2026, 4:00 PM EST
2.422
-0.148 (-5.75%)
Pre-market: Nov 9, 2026, 5:50 AM EST
Editas Medicine Employees
Editas Medicine had 87 employees as of December 31, 2025. The number of employees decreased by 159 or 64.63% compared to the previous year. That makes Editas Medicine the 32,246th largest employer in the world and 4,162nd in the United States.
Employees
87
Change (1Y)
-159
Growth (1Y)
-64.63%
Revenue / Employee
$540,287
Profits / Employee
-$849,989
Market Cap
394.70M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 87 | -159 | -64.63% |
| Dec 31, 2024 | 246 | -19 | -7.17% |
| Dec 31, 2023 | 265 | 39 | 17.26% |
| Dec 31, 2022 | 226 | -38 | -14.39% |
| Dec 31, 2021 | 264 | 29 | 12.34% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CorMedix | 191 |
| MapLight Therapeutics | 133 |
| C4 Therapeutics | 104 |
| Assembly Biosciences | 73 |
| Prothena Corporation | 67 |
| AgomAb Therapeutics NV | 62 |
| Tectonic Therapeutic | 60 |
| Rezolute | 58 |
EDIT News
- 25 days ago - Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference - GlobeNewsWire
- 4 weeks ago - Wells Fargo upgrades Editas Medicine after EDIT-401 study gets green light - TheFly
- 4 weeks ago - Editas Medicine upgraded to Overweight from Equal Weight at Wells Fargo - TheFly
- 4 weeks ago - Editas Medicine receives approval to initiate clinical trial of EDIT-401 - TheFly
- 4 weeks ago - Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia - GlobeNewsWire
- 6 weeks ago - Editas slips amid pressure on gene-editing sector after Anthropic update - TheFly
- 6 weeks ago - Editas Medicine upgraded to Buy at Guggenheim on EDIT-401 potential - TheFly
- 6 weeks ago - Editas Medicine upgraded to Buy from Neutral at Guggenheim - TheFly